Just over a year ago, New Zealand customs officials started intercepting batches of injectable medications labeled Fitaro and Orsema, developed by a little-known Bangladeshi drugmaker, Incepta Pharmaceuticals.
The injectable pens, 14 of which were seized at the border, contained semaglutide, a patented substance that helps control blood sugar levels and appetite and is the key ingredient in Novo Nordisk's blockbuster drugs Ozempic and Wegovy, according to data from New Zealand's medicines regulator Medsafe, reviewed by Reuters.
Reuters has found that the Incepta drugs are part of an Asia-based supply chain manufacturing and exporting cheaper copies of Ozempic worldwide, driven by a spike in global demand for the drug.
Ozempic was developed for type 2 diabetes but its active ingredient semaglutide is effective in promoting weight loss. The market for such weight-loss treatments, which Novo Nordisk is targeting with anti-obesity treatment Wegovy, is forecast to reach $150 billion by the early 2030s.
According to a Reuters review, at least 106,000 packs of semaglutide-based medicines made in Asia by Incepta have been shipped to 12 foreign markets including countries like the United States and Britain where Ozempic is protected by patents.
Incepta did not respond to multiple requests for comment about Fitaro and Orsema, which are approved for sale in Bangladesh, according to public records and information provided by a local regulatory official. The official with the Bangladesh Directorate General of Drug Administration, who declined to be named because he was not authorized to speak to the media, said Bangladeshi regulators had permitted Incepta to export Fitaro or Orsema but only provided it had won approval from receiving countries. The injectable pens, which are not authorized for use in New Zealand, were referred to Medsafe between August 2023 and May 2024 and destroyed, data from the regulator showed.
Medsafe told Reuters the Fitaro and Orsema batches that were destroyed appeared to be for personal use but did not comment on whether the medicines carried any health risk.
"Medicines that have been imported from overseas will not have been assessed and approved by Medsafe, so carry a significant risk as there is no assurance they have been made to an acceptable level of quality," the regulator added in response to a Reuters query about imports of semaglutide-based drugs.
Reuters has previously reported that semaglutide drugs from Bangladesh were sold on the India-based online marketplace IndiaMART. The latest reporting shows that the international distribution of semaglutide drugs not made by Novo Nordisk is much wider.
The data surveyed by Reuters came from pharmaceutical regulators in Australia, Brazil, New Zealand, and the United States; information from a commercial customs data provider for Kenya, Uzbekistan, Venezuela, Hong Kong, and the United Arab Emirates; and records of intercepted drugs from Britain, Switzerland, and Ireland.
In addition, an interview with a trade show exhibitor, a review of data from the commercial customs data provider, and from Brazil's Justice Ministry showed that six little-known companies, four of which are based in Asia, manufacture semaglutide-based medicines and that their products are shipped overseas.
At least three of these firms imported the key ingredient from China and at least one of their products was promoted online and in person outside the country of origin, according to the commercial customs data provider's data, an interview with an employee at a Chinese supplier Nanjing Hanxin Pharmaceutical Technology, and a website and social media app reviewed by Reuters.
These players take advantage of global patent exemptions allowed for less developed countries and instances of loose patent enforcement in countries including China, the Reuters review shows.
Novo Nordisk told Reuters it is the only approved manufacturer of semaglutide globally, and it could not vouch for the safety or effectiveness of products claiming to contain semaglutide made by other manufacturers.
Even though Novo Nordisk's semaglutide is protected by international licenses, countries like Bangladesh and Laos, classified as least developed nations by the United Nations, enjoy exemptions from industry patent rules.
The Danish firm, which has quickly become Europe's most valuable company with a market capitalization of around $400 billion, states on its website that it does not enforce patents in less developed countries. Given the frenzied demand for Ozempic, the financial impact of possible patent infringement on Novo Nordisk is currently limited. "Illegal versions of the drugs today do not cannibalize Novo's sales given they are selling every dose they can produce," said Nicholas Anderson, portfolio manager and managing director at global asset management firm Thornburg Investment Management, which owns Novo Nordisk stocks.
However, such copies are raising healthcare concerns. Medicines regulators in at least six countries including the U.S., Britain, and Ireland have rejected, destroyed, or seized some of Incepta's semaglutide-based drugs, according to drug regulator records and responses from regulators to Reuters' queries. In one case, unauthorized semaglutide was recalled in South Africa in December, because of potential health risks, according to a public notice posted in January by the local medicines regulator. The authority told Reuters the ingredient was sourced from a supplier in China not authorized to produce the ingredient in Ozempic, without providing more details.
"The semaglutide said to be found in this unauthorized substance, may contain unexpected impurities or degradation products which can have unknown effects on patients," the notice said.
Reuters found no evidence that these products would have caused any harm to patients, but their spread could add to public health concerns about a sector also threatened by fake Ozempic.